1472 results
Challenges and solutions in an expanding TAVI world
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session addresses key challenges and emerging solutions in today’s rapidly evolving TAVI landscape. It presents the latest evidence on valve replacement in low-risk patients with aortic stenosis, alongside strategies for navigating the complexities of lifetime management in TAVI candidates. The programme features a...
Degeneration of TAVI valves: a new target for innovations
19 May 2025 – From EuroPCR 2025
Discover the latest innovations targeting degeneration of TAVI valves, including expert presentations and cutting-edge technologies like The Splitter, an enabler for transcatheter aortic valve-in-valve implantation.
The Jon DeHaan Foundation Award competition
19 May 2025 – From EuroPCR 2025
Witness innovation in action at the Jon DeHaan Foundation Award competition featuring groundbreaking technologies like synchronized diaphragmatic stimulation for heart failure and novel devices for aortic bioprosthesis and interatrial shunting.
Learnings from LANDMARK and Compare-TAVI at 3 years
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.
LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...
How to manage the challenges of TAVI in bicuspid disease?
22 May 2025 – From EuroPCR 2025
How should TAVI be adapted to the unique challenges of bicuspid aortic valve disease? In this EuroPCR 2025 discussion, Chiara De Biase, Kentaro Hayashida, and Didier Tchetche explore the key anatomical and procedural considerations for tailoring treatment. From selecting which bicuspid anatomies are suitable for TAVI...
Redo TAVI: how to treat different TAVI platforms when they fail?
22 May 2025 – From EuroPCR 2025
In this EuroPCR 2025 interview, Tanja Rudolph, Dan Blackman, and Radoslaw Parma take a deep dive into the current understanding of redo TAVR.
Together, they address the main challenges faced in repeat procedures—chiefly, the risk of coronary obstruction and the importance of preserving coronary access, alongside strategies...
Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...
How will EARLY-TAVI and NOTION-3 impact TAVI practice?
21 May 2025 – From EuroPCR 2025
When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...
Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies
22 May 2025 – From EuroPCR 2025
Stroke remains one of the most feared complications of TAVI—for both patients and physicians. In this EuroPCR 2025 video interview, Bernard Prendergast and Rajesh Kharbanda examine the role of cerebral protection during TAVI procedures, in light of two randomised trials: PROTECTED TAVR and BHF PROTECT-TAVI. While...
Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis
21 May 2025 – From EuroPCR 2025
Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.
Patients with under-expanded valves faced higher risks...
What are the emerging indications for TAVI in 2025?
22 May 2025 – From EuroPCR 2025
Tiffany Patterson, Nicolas Van Mieghem, and Philippe Généreux discuss emerging indications for TAVI in 2025. They review recent evidence on asymptomatic severe aortic stenosis, highlighting four randomised trials—RECOVERY, AVATAR, ONLY TAVR, and EVoLVeD—that show TAVI or surgical AVR reduces hospitalisations for heart failure and trends toward...
Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study
21 May 2025 – From EuroPCR 2025
Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.
They review the trial design, patient characteristics, and results, comparing outcomes with...
How to manage coronary artery disease in TAVI candidates?
20 May 2025 – From EuroPCR 2025
Martine Gilard, Antonio Mangieri, and Marco Barbanti explore the strategy for handling coronary artery disease in patients undergoing TAVI. Is coronary angiography always required beforehand? Should PCI be performed in all cases—and if so, when? This exchange offers key insights to help guide your decisions on...
FAITAVI - Major Late-Breaking Trial from EuroPCR 2025
22 May 2025 – From EuroPCR 2025
Presented at EuroPCR 2025, the FAITAVI trial brings new insights into the management of coronary artery disease in patients undergoing TAVI.
In this PCR Perspectives video, Stephan Windecker and Flavio Ribichini explore how the trial—the first of its kind—compared angiography-guided versus FFR-guided strategies for intermediate coronary lesions....
ViV challenges in degenerated sutureless bioprosthesis
08 Apr 2025
Watch this EuroIntervention image to learn how the collision of a TAV device during valve crossing in ViV TAVI can potentially cause instability or dehiscence of the sutureless bioprosthesis, contributing to severe poorly tolerated PVL.
Overcoming anatomical challenges in the lifetime management of young TAVI patients
27 Mar 2025
Watch this replay with D. Tchetche, S. Bleiziffer, D. Dvir and D. Talreja and learn about the criteria for valve selection before TAVI in young patients, and so much more!
Use of advanced coronary techniques in bailout of aortic valvuloplasty balloon entrapment
25 Mar 2025
Balloon entrapment in valvuloplasty can be life-threatening, especially after balloon rupture. Learn about a new technique involving balloon internalisation and safety snares for successful retrieval and sheath upsizing.
Impact of transcatheter or surgical aortic valve performance on 5-year outcomes in patients at ≥ intermediate risk
12 Mar 2025
The objective of this study was to validate standardised clinical criteria for BVD and evaluate its association with mortality and rehospitalisation, thereby guiding optimal valve selection in clinical practice.
Reviewer
Clinical impact of TAVI frame under-expansion and optimisation strategies
07 Mar 2025
Watch this replay with C. Cook, M. Grygier, A. Khokhar and W-K. Kim to learn about the clinical importance of TAVI frame under-expansion, and so much more!
International Women's Day 2025: Raising awareness of aortic stenosis in women: - a silent killer
08 Mar 2025
It was a day in October last year when I had a meeting with patients’ group in UK. At the time, I needed to discuss with them why a registry on valvular heart disease and sex disparities is needed. The camaraderie was incredible and the discussion...
Author
